Panbela Announces Poster Presentation at American Association for Cancer Research 105 0 Kommentare

Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models

MINNEAPOLIS, April 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA)(“Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announces a poster presentation highlighting the results for ivospemin (SBP-101) as a polyamine metabolism modulator in ovarian cancer at the American Association for Cancer Research (AACR), which took place April 10, 2024. The work reflects the Company’s on-going collaboration with Johns Hopkins University School of Medicine.

“Ivospemin, reduces the viability of human ovarian adenocarcinoma cell lines regardless of their platinum sensitivity and we found that the combination treatment with doxorubicin increases median survival, delays tumor onset, and decreases overall tumor burden compared to either clinical or subclinical doxorubicin dosing schemes." said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. “The continued work by collaborators at Johns Hopkins University School of Medicine is providing the foundation for the initiation of our ovarian cancer program in this year.”

"The results suggest that SBP-101 in combination with doxorubicin may have a role in the clinical management of ovarian cancer, in particular the difficult to treat platinum-resistant population where few options exist,” said Dr. Simpson. “These studies continue to support the basis for moving into a clinical trial program in ovarian cancer with a goal of developing effective novel therapeutics in combination with standard of care for patients with unmet medical needs.”

The poster highlights the efficacy of SBP-101 in combination with doxorubicin which is used to treat platinum-resistant ovarian cancer. Treatment with doxorubicin significantly increases the in vitro toxicity of SBP-101 in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines. SBP-101 and doxorubicin cooperatively increase polyamine catabolism and decrease overall cell survival in vitro.

Lesen Sie auch

Novartis-Übernahme läuft

Verlust verzehnfacht: Morphosys muss "Karten auf den Tisch legen"

30.04.24, 13:30

Ihre wichtigsten Termine

Frische Q1-Zahlen von: Amazon, Mercedes-Benz, Adidas, Volkswagen und Lufthansa

30.04.24, 04:30

Earnings diese Woche

Diese Aktien haben Wall-Street-Schätzungen rasiert und könnten steigen!

29.04.24, 09:59

Ihre wichtigsten Termine

Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group

29.04.24, 04:30

Utilizing the immunocompetent VDID8⁺ murine ovarian cancer model (ID8⁺ C57Bl/6 ovarian cells overexpressing both VEGF and Defensin), the combination of SBP-101 and doxorubicin was evaluated significantly increased median mouse survival time. Cotreatment also results in delayed ascites formation and decreased overall tumor burden. The combination treatment cooperatively decreases overall ascitic polyamine content.

Seite 1 von 4

Seite 2 ►